Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660453 | 0.95 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL2660455 | 0.95 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL2662610 | 0.94 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL6984472 | 0.82 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL6971769 | 0.82 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL13211474 | 0.82 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL6973532 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL6974344 | 0.81 | ALDH1A1 (0.46) | ALDH1A1KMT2ACYP1A2CYP2C19KDM4E | |
| SCHEMBL16415765 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 | |
| SCHEMBL946915 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C19KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-2963043-B1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| CN-105008375-B | Tetrahydroimidazo [1,5-d ] [1,4] oxazepine derivatives | 卫材R&D管理有限公司 | 2016-12-28 | — | — | CN | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| US-9458176-B2 | Tetrahydroimidazo(1,5-D)[1,4]oxazepine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-2963043-A1 | TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-20150344467-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-12-03 | — | — | US | disclosed |
| US-20150344467-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-12-03 | — | — | US | disclosed |
| US-20150344467-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-12-03 | — | — | US | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| CN-1251589-A | Substituted triazolopyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME (GB) | 2000-04-26 | — | — | CN | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
| CN-1034539-A | The preparation method of hydrazides and hydroxamic acid derivs | SANDOZ LTD (CH) | 1989-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344467-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | PDE7A, ACHE, PDE5A | ALDH1A1 986/4885MEN1 3552/4885KMT2A 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.